GLPGF OTC
Lakefront Biotherapeutics
1W: +0.0%
1M: +21.8%
3M: +13.8%
YTD: +2.1%
1Y: -4.5%
3Y: -19.1%
5Y: -72.8%
$31.95
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$197M
+38.5% ▲
Capital Expenditures
$14M
+83.3% ▲
5Y CAGR: -31.6%
Free Cash Flow
-$211M
+47.6% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$5M
+95.1% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$103M | -$218M | $212M | $74M | $319M |
| Depreciation & Amort. | $35M | $66M | $44M | $45M | $0 |
| Stock-Based Comp. | $71M | $89M | $57M | $20M | $0 |
| Change in Working Capital | -$430M | -$351M | -$692M | -$321M | -$922M |
| Other Non-Cash Items | -$8M | -$88M | -$37M | -$137M | $405M |
| Operating Cash Flow | -$504M | -$501M | -$406M | -$320M | -$197M |
| — Investing Activities — | |||||
| Capital Expenditures | -$58M | -$37M | -$19M | -$82M | -$14M |
| Acquisitions (Net) | $29M | -$115M | -$7M | $0 | $20M |
| Investment Purchases | -$1.6B | -$2.7B | -$3.4B | -$3.4B | -$3.5B |
| Investment Sales | $2.1B | $1.6B | $3.5B | $3.7B | $3.7B |
| Other Investing | $11K | -$6M | $17M | $21M | $3M |
| Investing Cash Flow | $541M | -$1.2B | $71M | $221M | $228M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$7M | -$8M | -$7M | -$5M | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $3M | $7M | $2M | $0 | -$3M |
| Financing Cash Flow | -$4M | -$1M | -$5M | -$5M | -$3M |
| Net Change in Cash | $90M | -$1.7B | -$341M | -$103M | -$5M |
| Cash End of Period | $2.2B | $508M | $167M | $64M | $88M |
| Free Cash Flow | -$562M | -$537M | -$425M | -$402M | -$211M |